Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Wanjin Hong

4PUBLICATIONS
5CO-AUTHORS
Molecular targetsCell development, proliferation and death
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

Sort by Publication Date:
|Mar 18, 2026
Discovery of Pan-TEAD Inhibitors That Disrupt YAP-TEAD Interaction as a Potential Therapy for Gastric Cancers and Mutant KRAS and EGFR Lung Cancers.

Ramesh Kumar, Joanne Thian, Joel D W Toh

|Apr 12, 2024
Hippo Signaling at the Hallmarks of Cancer and Drug Resistance.

Ramesh Kumar, Wanjin Hong

|Oct 01, 2019
RNF4-A Paradigm for SUMOylation-Mediated Ubiquitination.

Ramesh Kumar, Kanaga Sabapathy

|Sep 28, 2018
Mitochondrial uncoupling reveals a novel therapeutic opportunity for p53-defective cancers.

R Kumar, L Coronel, B Somalanka

Pageof 1

Frequent Collaborators

1 joint publications

Kanaga Sabapathy

1 joint publications

CongBao Kang

1 joint publications

Jayantha Gunaratne

1 joint publications

Srinivasaraghavan Kannan

1 joint publications

Chandra S Verma

Frequent Collaborators

1 joint publications

Kanaga Sabapathy

1 joint publications

CongBao Kang

1 joint publications

Jayantha Gunaratne

1 joint publications

Srinivasaraghavan Kannan

Top Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on : Jun 26, 2019

8.5K
Monitoring Hippo Signaling Pathway Activity Using a Luciferase-based Large Tumor Suppressor (LATS) Biosensor
07:16

Monitoring Hippo Signaling Pathway Activity Using a Luciferase-based Large Tumor Suppressor (LATS) Biosensor

Published on : Sep 13, 2018

19.8K
<em>In Vitro</em> SUMOylation Assay to Study SUMO E3 Ligase Activity
09:45

<em>In Vitro</em> SUMOylation Assay to Study SUMO E3 Ligase Activity

Published on : Jan 29, 2018

9.7K
See more related videos

Top Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on : Jun 26, 2019

8.5K
Monitoring Hippo Signaling Pathway Activity Using a Luciferase-based Large Tumor Suppressor (LATS) Biosensor
07:16

Monitoring Hippo Signaling Pathway Activity Using a Luciferase-based Large Tumor Suppressor (LATS) Biosensor

Published on : Sep 13, 2018

19.8K
<em>In Vitro</em> SUMOylation Assay to Study SUMO E3 Ligase Activity
09:45

<em>In Vitro</em> SUMOylation Assay to Study SUMO E3 Ligase Activity

Published on : Jan 29, 2018

9.7K
See more related videos